Recommendations for the Use of Prolonged-Release Fampridine in
Patients with Multiple Sclerosis (MS)

J 2013

Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)

PREININGEROVA, Jana Lizrova, Ulf BAUMHACKL, Tunde CSEPANY, Adam CZAPLINSKI, Florian DEISENHAMMER et. al.

Základní údaje

Originální název

Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)

Autoři

Vydání

CNS NEUROSCIENCE &THERAPEUTICS, HOBOKEN, WILEY-BLACKWELL, 2013, 1755-5930

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.784

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1111/cns.12101

UT WoS

000318112800003

Klíčová slova anglicky

Aminopyridines; Fampridine; Multiple sclerosis; Walking

Štítky

ne MU

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 1. 2014 14:27, Olga Křížová

Anotace

V originále

Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.

Citovat

PREININGEROVA, Jana Lizrova, Ulf BAUMHACKL, Tunde CSEPANY, Adam CZAPLINSKI, Florian DEISENHAMMER, Tobias DERFUSS, Tanja H. FABJAN, Franz FAZEKAS, Siegrid FUCHS, Eva HAVRDOVA, Alenka Horvath LEDINEK, Zsolt ILLES, Sasa Sega JAZBEC, Eleonora KLIMOVA, Samuel KOMOLY, Egon KURCA, Michael LINNEBANK, Lubomir LISY, Jan MARES, Lubica PROCHAZKOVA, Rozsa CSILLA, Jarmila SZILASIOVA, Pavel ŠTOURAČ, Radomir TALAB, Peter TURCANI, Marta VACHOVA, Laszlo VECSEI, David VODUSEK, Olga ZAPLETALOVA a Thomas BERGER. Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS). CNS NEUROSCIENCE &THERAPEUTICS. HOBOKEN: WILEY-BLACKWELL, 2013, roč. 19, č. 5, s. 302-306. ISSN 1755-5930. Dostupné z: https://dx.doi.org/10.1111/cns.12101.

@article{1160091,
   author = {Preiningerova, Jana Lizrova and Baumhackl, Ulf and Csepany, Tunde and Czaplinski, Adam and Deisenhammer, Florian and Derfuss, Tobias and Fabjan, Tanja H. and Fazekas, Franz and Fuchs, Siegrid and Havrdova, Eva and Ledinek, Alenka Horvath and Illes, Zsolt and Jazbec, Sasa Sega and Klimova, Eleonora and Komoly, Samuel and Kurca, Egon and Linnebank, Michael and Lisy, Lubomir and Mares, Jan and Prochazkova, Lubica and Csilla, Rozsa and Szilasiova, Jarmila and Štourač, Pavel and Talab, Radomir and Turcani, Peter and Vachova, Marta and Vecsei, Laszlo and Vodusek, David and Zapletalova, Olga and Berger, Thomas},
   article_location = {HOBOKEN},
   article_number = {5},
   doi = {http://dx.doi.org/10.1111/cns.12101},
   keywords = {Aminopyridines; Fampridine; Multiple sclerosis; Walking},
   language = {eng},
   issn = {1755-5930},
   journal = {CNS NEUROSCIENCE &THERAPEUTICS},
   title = {Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)},
   volume = {19},
   year = {2013}
}

TY  - JOUR
ID  - 1160091
AU  - Preiningerova, Jana Lizrova - Baumhackl, Ulf - Csepany, Tunde - Czaplinski, Adam - Deisenhammer, Florian - Derfuss, Tobias - Fabjan, Tanja H. - Fazekas, Franz - Fuchs, Siegrid - Havrdova, Eva - Ledinek, Alenka Horvath - Illes, Zsolt - Jazbec, Sasa Sega - Klimova, Eleonora - Komoly, Samuel - Kurca, Egon - Linnebank, Michael - Lisy, Lubomir - Mares, Jan - Prochazkova, Lubica - Csilla, Rozsa - Szilasiova, Jarmila - Štourač, Pavel - Talab, Radomir - Turcani, Peter - Vachova, Marta - Vecsei, Laszlo - Vodusek, David - Zapletalova, Olga - Berger, Thomas
PY  - 2013
TI  - Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)
JF  - CNS NEUROSCIENCE &THERAPEUTICS
VL  - 19
IS  - 5
SP  - 302-306
EP  - 302-306
PB  - WILEY-BLACKWELL
SN  - 17555930
KW  - Aminopyridines
KW  - Fampridine
KW  - Multiple sclerosis
KW  - Walking
N2  - Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.
ER  -

PREININGEROVA, Jana Lizrova, Ulf BAUMHACKL, Tunde CSEPANY, Adam CZAPLINSKI, Florian DEISENHAMMER, Tobias DERFUSS, Tanja H. FABJAN, Franz FAZEKAS, Siegrid FUCHS, Eva HAVRDOVA, Alenka Horvath LEDINEK, Zsolt ILLES, Sasa Sega JAZBEC, Eleonora KLIMOVA, Samuel KOMOLY, Egon KURCA, Michael LINNEBANK, Lubomir LISY, Jan MARES, Lubica PROCHAZKOVA, Rozsa CSILLA, Jarmila SZILASIOVA, Pavel ŠTOURAČ, Radomir TALAB, Peter TURCANI, Marta VACHOVA, Laszlo VECSEI, David VODUSEK, Olga ZAPLETALOVA a Thomas BERGER. Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS). \textit{CNS NEUROSCIENCE \&{}THERAPEUTICS}. HOBOKEN: WILEY-BLACKWELL, 2013, roč.~19, č.~5, s.~302-306. ISSN~1755-5930. Dostupné z: https://dx.doi.org/10.1111/cns.12101.

Podrobný výpis o publikaci